Cemiplimab

<!-- Name:DistributionId Value:8756353 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

Oslo, 20 December 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor…